---
document_datetime: 2023-09-21 18:38:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/savene-epar-procedural-steps-taken-authorisation_en.pdf
document_name: savene-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4112296
conversion_datetime: 2025-12-19 04:36:05.745992
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1 Submission of the dossier

The applicant TopoTarget A/S submitted on 27 th July 2005 an application for Marketing Authorisation to the European Medicines Agency (EMEA) through the centralised procedure for Savene, which was designated  as  an  orphan  medicinal  product  EU/3/01/059  on  19  September  2001.  Savene  was designated as an orphan medicinal product in the following indication:  Treatment of anthracycline extravasation. The estimated prevalence of this condition was approximately 0.03 in 10,000 persons in the Community, at the time the application for orphan designation was made.

The applicant applied for the following indication: 'Treatment of anthracycline extravasation'.

The application submitted is a complete dossier: composed of administrative information, complete quality  data,  non-clinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and/or bibliographic literature substituting/supporting certain tests or studies.

## Protocol Assistance

None.

## Licensing status

The product was not licensed for treatment of anthracycline extravasation in any country at the time of submission of the application.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Dr Eric Abadie Co-Rapporteur: Dr. Jens Ersb√∏ll

## 2 Steps taken for the assessment of the product

- The application was received by the EMEA on 27 July 2005.
- The procedure started on 17 August 2005.
- The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 27 October 2005 (Annex 4.1). The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 1 November 2005.
- During  the  meeting  on  14  December  2005,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 15 December 2005.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 17 February 2006.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  24 March 2006.
- During the CHMP meeting on 27 April 2006, the CHMP agreed on a List of Outstanding Issues to be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP  List  of Outstanding Issues on 2 May 2006.
- The Rapporteurs circulated the Final Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 19 May 2006
- During  the  meeting  on    29  May-1  June  2006,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Savene on 1 June 2006. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 23 May 2006.
- The  European  Commission  granted  a  marketing  authorisation  valid  throughout  the  European Union for Savene on 28 July 2006.